PMID- 21220034
OWN - NLM
STAT- MEDLINE
DCOM- 20110913
LR  - 20151119
IS  - 1523-6536 (Electronic)
IS  - 1083-8791 (Linking)
VI  - 17
IP  - 6
DP  - 2011 Jun
TI  - Increased copy number of the interleukin-6 receptor gene is associated with 
      adverse survival in multiple myeloma patients treated with autologous stem cell 
      transplantation.
PG  - 810-20
LID - 10.1016/j.bbmt.2011.01.002 [doi]
AB  - Interleukin-6 (IL-6) is a potent pleiotropic cytokine that regulates plasma cell 
      (PC) growth via the IL-6 receptor (IL-6R). We hypothesized that up-regulation of 
      IL-6R in myeloma cells might confer the growth privilege to myeloma cells over 
      bone marrow (BM) hematopoietic cells. We investigated the frequency and 
      prognostic implication of increased copy number of the IL-6R gene by fluorescence 
      in situ hybridization (FISH) in patients with newly diagnosed multiple myeloma 
      (MM). One hundred two patients with newly diagnosed MM were enrolled. The FISH 
      study for IL-6R was performed using a homemade bacterial artificial chromosome 
      (BAC) probe for IL6R at chromosome 1q21. FISH signals were counted among BM 
      plasma cells sorted by cytoplasmic immunoglobulin light chain staining (cIg 
      FISH). The amplification of IL-6R was detected in 53/102 patients (52.0%). The 
      5-year overall survival (OS) rate of patients with IL-6R gene amplification was 
      41.3% versus 44.8% for those with a normal IL-6R (P = .425). In 44 patients 
      treated with high-dose chemotherapy and autologous stem cell transplantation 
      (ASCT), patients with >/=3.1 copy numbers of IL-6R per PC showed adverse 5-year OS 
      compared to those with <2.1 copies of IL-6R gene (44.4% versus 78.0%, P = .024). 
      In multivariate analysis, the increase of IL-6R copy numbers (mean copy/PC >/=3.1) 
      could be considered as an independent prognostic factor for MM patients who 
      underwent ASCT. The gain of the IL-6R gene was frequent in myeloma, showing an 
      association with adverse prognosis in myeloma patients treated with ASCT. These 
      findings suggest the potential role of IL-6R in myeloma cell growth and 
      therapeutic implications of the IL-6R blocker in the future.
CI  - Copyright (c) 2011 American Society for Blood and Marrow Transplantation. Published 
      by Elsevier Inc. All rights reserved.
FAU - Kim, Seon Young
AU  - Kim SY
AD  - Department of Laboratory Medicine, Seoul National University College of Medicine, 
      Seoul, South Korea.
FAU - Min, Hyun Jung
AU  - Min HJ
FAU - Park, Hyun Kyung
AU  - Park HK
FAU - Oh, Bora
AU  - Oh B
FAU - Kim, Tae Young
AU  - Kim TY
FAU - She, Cha Ja
AU  - She CJ
FAU - Hwang, Sang Mee
AU  - Hwang SM
FAU - Kim, Miyoung
AU  - Kim M
FAU - Kim, Hyun Kyung
AU  - Kim HK
FAU - Kim, Inho
AU  - Kim I
FAU - Yoon, Sung-Soo
AU  - Yoon SS
FAU - Park, Seonyang
AU  - Park S
FAU - Kim, Byoung Kook
AU  - Kim BK
FAU - Lee, Jae Hoon
AU  - Lee JH
FAU - Lee, Dong Soon
AU  - Lee DS
CN  - Korea Multiple Myeloma Working Party
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110108
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for 
      Blood and Marrow Transplantation
JID - 9600628
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Immunoglobulin Light Chains)
RN  - 0 (Interleukin-6)
RN  - 0 (Receptors, Interleukin-6)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/administration & dosage
MH  - Biomarkers/analysis
MH  - Chromosomes, Human, Pair 1/genetics
MH  - Female
MH  - *Gene Dosage
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Immunoglobulin Light Chains/analysis
MH  - In Situ Hybridization, Fluorescence
MH  - Interleukin-6/metabolism
MH  - Male
MH  - Multiple Myeloma/*genetics/*mortality/pathology/*therapy
MH  - Multivariate Analysis
MH  - Plasma Cells/*metabolism/pathology
MH  - Prognosis
MH  - *Receptors, Interleukin-6/genetics/metabolism
MH  - Survival Rate
MH  - Transplantation, Autologous
EDAT- 2011/01/12 06:00
MHDA- 2011/09/14 06:00
CRDT- 2011/01/12 06:00
PHST- 2010/09/08 00:00 [received]
PHST- 2011/01/03 00:00 [accepted]
PHST- 2011/01/12 06:00 [entrez]
PHST- 2011/01/12 06:00 [pubmed]
PHST- 2011/09/14 06:00 [medline]
AID - S1083-8791(11)00005-X [pii]
AID - 10.1016/j.bbmt.2011.01.002 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 2011 Jun;17(6):810-20. doi: 
      10.1016/j.bbmt.2011.01.002. Epub 2011 Jan 8.